Contract research organisation (CRO) Altasciences is expanding its formulation, manufacturing and analytical services in the US as part of a project with the biopharmaceutical company Alladapt Immunotherapeutics.
Altasciences is building dedicated facilities for Alladapt to help with the company’s Phase III and commercial requirements.
Altasciences had originally developed the formulation and manufacturing processes to meet all of Alladapt’s Phase I and II clinical trial needs. Now, the company has been contracted to continue the process with the construction of a new 53,000-square-foot building that will meet Alladapt’s Phase III and commercial requirements.
Altasciences will manage all aspects of the project and the building will have additional client dedicated capacity that can be used for Phase I through to commercial manufacturing services.
“We are pleased to continue supporting Alladapt in their important goal of developing a single therapeutic to address a wide range of mono- and multi-food allergies, and we look forward to fulfilling their Phase III and commercial requirements,” stated Ben Reed, General Manager, CDMO Services at Altasciences.
“The training Altasciences provides their CDMO workforce is second to none, as each team member is well-equipped to optimise and complete our manufacturing projects. We are proud to partner with Altasciences to continue advancing the clinical development of our potentially best in-class oral immunotherapy candidate, ADP101,” said Ashley Dombkowski, Chief Executive Officer and co-founder at Alladapt.